结论肝细胞癌患者多出现血清铁蛋白升高；
Conclusions Most of the patients with hepatocellular carcinoma have elevated serum ferritin levels.
材料与方法：对49例肝细胞癌患者进行了双时相螺旋CT扫描。
Meterials and methods: Dual phase helical CT of the liver was done in 49 patients with known or suspected hepatocellular carcinoma.
在中国和远东，超过80%的肝细胞癌患者有慢性乙肝病毒的感染。
In parts of China and the Far East, over 80% of HCC patients have chronic HBV infection.
结论非特异性免疫治疗可提高射频消融后肝细胞癌患者的免疫功能。
Conclusion Non-specific immune treatment can improve the immune function in HCC after RFA.
联合这些分子标志物能帮助提高器官在HCV -肝细胞癌患者中的分配。
Incorporation of these molecular markers could help to improve organ allocation for HCV-HCC patients.
结论门静脉受侵肝细胞癌患者的预后与肝癌分期、肿瘤的数目和治疗方法密切相关。
Conclusion the prognosis of HCC patients with portal vein invasion is closely related with patient's HCC stage, number of tumors and methods of therapy.
摘要 ：目的探讨非特异性免疫治疗对射频消融术后肝细胞癌患者免疫功能的影响。
Abstract : Objective To investigate the effect of radiofrequency ablation combined sequential nonspecific immune treatment on patient with hepatic carcinoma.
根据目前通用的临床分类可以把肝细胞癌患者分成5期，每一期都有一个特定的针对治疗方案。
The current clinical classification of HCC divides patients into 5 stages with a specific treatment-oriented schedule.
目的：检测肝细胞癌患者血清血管内皮生长因子与基质金属蛋白酶- 9含量并分析与临床分期的相关性。
Objective to detect the concentration of serum vascular endothelial growth factor and matrix metalloproteinase-9 in hepatocellular carcinoma and analyze their relation with the clinical stages.
方法：收集1995—2000年在复旦大学肝癌研究所行手术切除的355例肝细胞癌患者临床病理资料及术后随访资料。
Methods: a retrospective analysis of clinicopathological data of 355 patients with hepatocellular carcinoma who received hepatic resection in our hospital from 1995 to 2000.
《国际肝病》：肝细胞癌常常发生于肝硬化患者，如何在这些患者中早期发现HCC ？
International Digest: Hepatocelluar cancer (HCC) is frequently occurred in patients with cirrhosis. How can we detect HCC early in these patients?
该研究为处于肝细胞癌（HCC）发病危险中的患者带来了希望，研究人员说。
The study carries hope for patients at risk from hepatocellular carcinoma (HCC), researchers said.
乙肝患者经历以下的疾病状态：病毒抑制、病毒血症期、血清转化、肝细胞癌、肝硬化和死亡。
Patients cycled between the following health states: viral suppression, ongoing viremia, seroconversion, hepatocellular carcinoma, cirrhosis and death.
目的：用SELDI蛋白质芯片技术检测HBV感染携带者与肝细胞癌（HCC）患者血清蛋白质谱的差异性表达，以发现HCC的早期诊断标志物。
Object Using SELDI protein chip technology to detect the different serum protein spectrum of HBV infected carriers and HCC patient , and to explore serum markers for diagnosis of HCC.
本文应用彩色多普勒对23例原发性肝细胞癌(HCC)患者肝动脉栓塞术(TAE)前后门静脉的血流动力学变化进行了研究。
Changes of portal venous hemodynamics after transcatheter hepatic artery embolization (TAE) were studied in 23 hepatocellular carcinoma (HCC) patients using the color Doppler system.
肝移植是肝细胞癌(HCC)患者最有希望的治疗选择之一。
Liver transplantation is one of the therapeutic methods with great promise to treat hepatocellular carcinoma (HCC).
FHIT基因的改变在肝细胞癌中是早期频发的事件，可以成为肝癌患者预后一种新的分子指标。
The alternation of FHIT gene is an early and frequent event of liver cancer, and FHIT gene as a new molecular indicator of liver cancer can monitor the prognosis of liver cancer patients.
肝细胞癌是临床常见的恶性肿瘤，传统的手术及化疗难以使患者受益。
Hepatocellular carcinoma is a common malignant tumor, traditional surgery and chemotherapy provide unremarkable benefit.
这些数据表明，NASH患者发生HCC的风险性，与HCV相关性肝硬化患者发生肝细胞癌的风险性相当。
These figures suggest that NASH carries a risk of HCC that rivals the risk in patients with HCV-cirrhosis.
结论：这里我们鉴别了在等待肝移植的HCV -肝癌患者中，和肝细胞癌进展相关的基因。
CONCLUSIONS: Here, we have identified genes associated with HCC progression in HCV-HCC patients awaiting LT transplantation.
研究者们还分析了患者的甲胎蛋白水平（AFP）（肝细胞癌的特定生物标记），发现较高集落得分的患者其甲胎蛋白水平也较高。
Researchers also analyzed levels of alpha-fetoprotein (AFP), a specific biomarker of HCC, and found that patients with higher CFU scores had higher levels of AFP.
摘要：目的分析外科医师手术操作对肝细胞癌(HCC)患者预后的影响因素。
ABSTRACT: Objective to evaluate the prognostic value of surgical operation-related factors in patients with hepatocellular carcinoma (HCC).
由于缺乏预测进展和复发的肿瘤标志物那些有可能被治疗的更高阶段的肝细胞癌的患者被拒绝用肝移植疗法。
Potentially curable higher-stage HCC patients are denied LT due to the lack of cancer markers that predict progression and recurrence.
由于缺乏预测进展和复发的肿瘤标志物那些有可能被治疗的更高阶段的肝细胞癌的患者被拒绝用肝移植疗法。
Potentially curable higher-stage HCC patients are denied LT due to the lack of cancer markers that predict progression and recurrence.
应用推荐